All ABUS Content

Analysis

Arbutus Biopharma 2025 Financial Review

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious diseases. For the year ended December 31, 2025, Arbutus...

March 24, 20261 min read

Arbutus Biopharma Corp (ABUS) Q2 2022 Earnings Call

Arbutus Biopharma Corp (NASDAQ: ABUS) Q2 2022 Earnings Conference

August 1, 20221 min read

Arbutus Biopharma Corp (ABUS) Q1 2022 earnings call

Arbutus Biopharma Corp (NASDAQ: ABUS) Q1 2022 Earnings Conference

May 2, 20221 min read

Arbutus Biopharma Corp (ABUS) Q4 2021 Earnings Conference Call

Arbutus Biopharma Corp (NASDAQ: ABUS) Q4 2021 Earnings Conference

February 23, 20221 min read

Arbutus Biopharma Corp (ABUS) Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update

Arbutus Biopharma Corp (NASDAQ: ABUS) Q3 2021 Earnings Conference

November 8, 20211 min read

Arbutus Biopharma Corp (ABUS) 2Q21 Earnings Call

Arbutus Biopharma Corp (NASDAQ: ABUS) Q2 2021 Earnings Conference

August 9, 20211 min read

Arbutus Biopharma Corp (ABUS) Arbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update

Arbutus Biopharma Corp (NASDAQ: ABUS) Q4 2020 Earnings Conference

February 26, 20211 min read

Market News

Arbutus Biopharma (ABUS): FY19 Earnings Snapshot

— Arbutus Biopharma Corporation (NASDAQ:ABUS) reported a net loss of $164.9 million or $2.89 per share for fiscal 2019, compared to a loss of $67.2…

March 5, 20201 min read